| Latest | F'cast | |
|---|---|---|
| Div Yield | 1.8% | 0.0% |
| Div Cover | 3.4 | n/a |
| Op Mrgn | -3.6% | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | 16.6 | n/a |
| PEG | 0.7 | n/a |
| Pr/Revenue | 1.7 | n/a |
| Pr/Book | 1.7 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 3.5% | n/a |
| PBT | n/a | n/a |
| EPS | 23.6% | n/a |
| DPS | 90.5% | n/a |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | 751.30 | (68.80) | 6.60¢ | 23.4 | n/a | -48% | n/a | 0.0% |
| 31-Dec-21 | 709.40 | (7.50) | 8.40¢ | 21.0 | 0.8 | +27% | n/a | 0.0% |
| 31-Dec-22 | 736.40 | (54.80) | 11.10¢ | 14.6 | 0.5 | +32% | n/a | 0.0% |
| 31-Dec-23 | 713.40 | 39.70 | 11.00¢ | 15.6 | n/a | -1% | 2.10¢ | 1.2% |
| 31-Dec-24 | 738.30 | (49.60) | 13.60¢ | 14.3 | 0.6 | +24% | 4.00¢ | 2.1% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Total Voting Rights | 02-Jan-2026 | 11:10 | RNS |
| Confirmation of Board changes | 02-Jan-2026 | 07:00 | RNS |
| Confirmation of Board changes | 02-Jan-2026 | 07:00 | RNS |
| Confirmation of Board changes | 02-Jan-2026 | ShareCast |
| Director/PDMR Shareholding | 24-Dec-2025 | ShareCast |
| Elementis buys Alchemy Ingredients for $22m | 26-Nov-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 168.00p |
| Change Today | -2.60p |
| % Change | -1.52 % |
| 52 Week High | 176.60p |
| 52 Week Low | 115.00p |
| Volume | 1,030,720 |
| Shares Issued | 569.30m |
| Market Cap | £956.42m |
| Beta | 1.09 |
| RiskGrade | 191 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Interim | Final | |
| Ex-Div | 14-Aug-25 | 01-May-25 |
| Paid | 26-Sep-25 | 30-May-25 |
| Amount | 1.30¢ | 2.90¢ |
| Time | Volume / Share Price |
| 16:35 | 352,672 @ 168.00p |
| 16:35 | 561 @ 168.00p |
| 16:35 | 1,733 @ 168.00p |
| 16:35 | 4,662 @ 168.00p |
| 16:35 | 3,541 @ 168.00p |
| CEO | Luc van Ravenstein |
| CFO | Kath Kearney-Croft |
You are here: research